Wangji Li
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Wangji Li has a total of 20 co-authors. Here are the top co-authors by number of shared publications:
Changda Ye
Southern Medical University (The First People’s Hospital of Shunde, Foshan)
1 shared publicationDonghua Huang
Department of Health Management Nanfang Hospital Southern Medical University Guangzhou China
1 shared publicationGuoxin Li
Department of General Surgery Nanfang Hospital Southern Medical University Guangzhou China
1 shared publicationHao Liu
Department of General Surgery Nanfang Hospital Southern Medical University Guangzhou China
1 shared publicationJunjie Feng
Department of Laboratory Medicine Nanfang Hospital Southern Medical University Guangzhou China
1 shared publicationManzhao Ouyang
Southern Medical University (The First People’s Hospital of Shunde, Foshan)
1 shared publication
Latest Publications
- Open Access
- 21 August 2026
- Published by SAGE Publications in Clinical Medicine Insights: Oncology
- Vol. 20
Impact of Preoperative Anemia on Short-Term Outcomes After Colorectal Cancer Surgery: How the Choice of Diagnostic Criteria Leads to Conflicting Findings
Background: Whether preoperative anemia is independently associated with short-term postoperative outcomes in colorectal cancer (CRC) remains controversial. This study investigated the association between preoperative anemia and 30-day postoperative complications (PO30C) and evaluated how different anemia diagnostic criteria influence this association. Methods: In this retrospective cohort study, patients who underwent radical CRC surgery from January 2018 to January 2021 were consecutively enrolled. Firth’s regression was used for univariate and multivariable analysis to evaluate the impact of preoperative anemia on short-term outcomes after CRC surgery. Dose-response analysis assessed the relationship between anemia severity and PO30C. Sensitivity analysis compared the association under WHO and China’s anemia criteria, and misclassification analysis characterized criteria-related differences. Population-based examination of the misclassification mechanism was performed using China Health and Retirement Longitudinal Study (CHARLS) data. Internal validation used 10-fold cross-validation and bootstrap resampling. Results: Among 231 patients, 108 (46.8%) had preoperative anemia and 29 (12.6%) developed PO30C. Multivariable analysis showed that preoperative anemia (OR = 2.39, 95% CI: 1.04–5.81, P = 0.039) and male sex (OR = 3.11, 95% CI: 1.23–9.24, P = 0.015) were independently associated with PO30C. A significant dose-response relationship was observed across anemia severity groups (P-trend = 0.005), with moderate-to-severe anemia independently associated with PO30C (OR = 2.88, 95% CI: 1.04–8.03, P = 0.042). The association was significant under China criteria (P = 0.039) but not under WHO criteria (P = 0.075). Misclassification analysis revealed that WHO criteria reclassified 33 borderline patients as anemic, whose PO30C rate (9.1%) resembled the normal group (6.7%) rather than the anemia group (18.5%), thereby attenuating the association. CHARLS data corroborated this misclassification mechanism. The model showed moderate discrimination (optimism-corrected C-index = 0.704). Conclusion: Preoperative anemia was independently associated with PO30C under the China criteria, whereas WHO criteria attenuated this association through misclassification of low-risk borderline patients. Population-appropriate diagnostic criteria are important for perioperative risk estimation and may explain conflicting findings in the existing literature.
- 21 August 2026
- Published by SAGE Publications in Clinical Medicine Insights: Oncology
- Vol. 20
Open AccessImpact of Preoperative Anemia on Short-Term Outcomes After Colorectal Cancer Surgery: How the Choice of Diagnostic Criteria Leads to Conflicting Findings
Background: Whether preoperative anemia is independently associated with short-term postoperative outcomes in colorectal cancer (CRC) remains controversial. This study investigated the association between preoperative anemia and 30-day postoperative complications (PO30C) and evaluated how different anemia diagnostic criteria influence this association. Methods: In this retrospective cohort study, patients who underwent radical CRC surgery from January 2018 to January 2021 were consecutively enrolled. Firth’s regression was used for univariate and multivariable analysis to evaluate the impact of preoperative anemia on short-term outcomes after CRC surgery. Dose-response analysis assessed the relationship between anemia severity and PO30C. Sensitivity analysis compared the association under WHO and China’s anemia criteria, and misclassification analysis characterized criteria-related differences. Population-based examination of the misclassification mechanism was performed using China Health and Retirement Longitudinal Study (CHARLS) data. Internal validation used 10-fold cross-validation and bootstrap resampling. Results: Among 231 patients, 108 (46.8%) had preoperative anemia and 29 (12.6%) developed PO30C. Multivariable analysis showed that preoperative anemia (OR = 2.39, 95% CI: 1.04–5.81, P = 0.039) and male sex (OR = 3.11, 95% CI: 1.23–9.24, P = 0.015) were independently associated with PO30C. A significant dose-response relationship was observed across anemia severity groups (P-trend = 0.005), with moderate-to-severe anemia independently associated with PO30C (OR = 2.88, 95% CI: 1.04–8.03, P = 0.042). The association was significant under China criteria (P = 0.039) but not under WHO criteria (P = 0.075). Misclassification analysis revealed that WHO criteria reclassified 33 borderline patients as anemic, whose PO30C rate (9.1%) resembled the normal group (6.7%) rather than the anemia group (18.5%), thereby attenuating the association. CHARLS data corroborated this misclassification mechanism. The model showed moderate discrimination (optimism-corrected C-index = 0.704). Conclusion: Preoperative anemia was independently associated with PO30C under the China criteria, whereas WHO criteria attenuated this association through misclassification of low-risk borderline patients. Population-appropriate diagnostic criteria are important for perioperative risk estimation and may explain conflicting findings in the existing literature.
- Open Access
- 16 March 2024
- Published by Wiley in Interdisciplinary Medicine
- Vol. 2 (3)
PDE5 inhibitors against cancer via mediating immune cells in tumor microenvironment: AI‐based approach for future drug repurposing exploration
Phosphodiesterase‐5 (PDE5) inhibitors are used clinically for the treatment of erectile dysfunction, pulmonary arterial hypertension, and other urological diseases. Emerging evidences have suggested the therapeutic capacity of PDE5 inhibitors as the repurposed drugs in oncology. However, the essential immune function of PDE5 inhibitors against cancer in tumor microenvironment (TME) remains unclear. This review aimed to summarize the recent advances regarding the repurposing of PDE5 inhibitors as anti‐cancer agents for cancer management to enhance the anti‐tumor immune response by mediating various immune cells, which included the myeloid‐derived suppressor cells, macrophages, T cells, fibroblasts, and natural killer cells in TME. Moreover, artificial intelligence (AI), as a new approach, is composed of traditional machine learning and deep learning methods and could be potentially used to identify the targets of immune cells in TME and predict the efficacy for repurposed drug toward malignancies. In summary, these endeavors provide novel insights into the comprehensive strategies for PDE5 inhibitors mediating immune cells against cancer and AI‐based approach for future drug repurposing exploration.
- 16 March 2024
- Published by Wiley in Interdisciplinary Medicine
- Vol. 2 (3)
Open AccessPDE5 inhibitors against cancer via mediating immune cells in tumor microenvironment: AI‐based approach for future drug repurposing exploration
Phosphodiesterase‐5 (PDE5) inhibitors are used clinically for the treatment of erectile dysfunction, pulmonary arterial hypertension, and other urological diseases. Emerging evidences have suggested the therapeutic capacity of PDE5 inhibitors as the repurposed drugs in oncology. However, the essential immune function of PDE5 inhibitors against cancer in tumor microenvironment (TME) remains unclear. This review aimed to summarize the recent advances regarding the repurposing of PDE5 inhibitors as anti‐cancer agents for cancer management to enhance the anti‐tumor immune response by mediating various immune cells, which included the myeloid‐derived suppressor cells, macrophages, T cells, fibroblasts, and natural killer cells in TME. Moreover, artificial intelligence (AI), as a new approach, is composed of traditional machine learning and deep learning methods and could be potentially used to identify the targets of immune cells in TME and predict the efficacy for repurposed drug toward malignancies. In summary, these endeavors provide novel insights into the comprehensive strategies for PDE5 inhibitors mediating immune cells against cancer and AI‐based approach for future drug repurposing exploration.